Propanc Biopharma Files 8-K: Material Agreement & Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $49,200, $41,000, $49,200.00, $7,380.00, $28,290 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma signed a deal creating debt and sold stock.
AI Summary
On June 17, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits.
Why It Matters
This filing indicates Propanc Biopharma has entered into a significant agreement that creates a financial obligation and has also engaged in the sale of equity, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement creating a financial obligation and unregistered sales of equity, which can introduce financial risks and dilution.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- June 17, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Propanc Biopharma, Inc. enter into?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement on June 17, 2024, which resulted in a direct financial obligation.
What other significant event is reported in this 8-K filing?
In addition to the material definitive agreement, the filing also reports on the creation of a direct financial obligation and unregistered sales of equity securities.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 17, 2024.
What are the standard industrial classifications for Propanc Biopharma, Inc.?
Propanc Biopharma, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the state of incorporation for Propanc Biopharma, Inc.?
Propanc Biopharma, Inc. is incorporated in Delaware.
Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-21 08:59:52
Key Financial Figures
- $49,200 — ny in the aggregate principal amount of $49,200 (the "Note"), for a purchase price of $
- $41,000 — 0 (the "Note"), for a purchase price of $41,000. The Company intends to use the net pro
- $49,200.00 — on the Issuance Date to the Principal ($49,200.00 * fifteen percent (15%) = $7,380.00). A
- $7,380.00 — l ($49,200.00 * fifteen percent (15%) = $7,380.00). Accrued, unpaid interest and outstand
- $28,290 — with the first on December 15, 2024 for $28,290.00, and the other four payments on Janu
- $56,580.00 — 72.50 (a total payback to the Holder of $56,580.00). The Company shall have a five (5) day
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex4-1.htm (EX-4.1) — 100KB
- ex10-1.htm (EX-10.1) — 79KB
- 0001493152-24-024632.txt ( ) — 427KB
- ppcb-20240617.xsd (EX-101.SCH) — 3KB
- ppcb-20240617_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240617_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 21, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer